Preoperative Intravitreal Conbercept Injection Reduced Both Angiogenic and Inflammatory Cytokines in Patients With Proliferative Diabetic Retinopathy
Journal of Diabetes Research · 2024
DOI: 10.1155/2024/2550367 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Diabetes Research, 2024. Verfasst von Zijing Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Joint Shantou International Eye Center of Shantou University and The Chinese University of Hong Kong, Shantou, Guangdong, China. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Intravitreal Injections, Recombinant Fusion Proteins, Cytokines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Aims
To investigate the impact of intravitreal injection of conbercept, a recombinant fusion protein with decoy receptors for the vascular endothelial growth factor (VEGF) family, on intraocular concentrations of angiogenic and inflammatory mediators in patients with proliferative diabetic retinopathy (PDR), analyzed its potential impact on surgical outcomes.
Methods
Forty eyes from 40 patients with PDR were included in this prospective study. Patients received intravitreal injection of conbercept followed by vitrectomy or phacovitrectomy in 1 week. Aqueous humor samples were collected before and 1 week after the conbercept injection. The concentrations of angiogenic and inflammatory cytokines and chemokines were measured by flow cytometry. Follow‐up clinical data were collected and analyzed.
Results
Intravitreal conbercept injection significantly decreased aqueous concentrations of VEGF (325.5 (baseline) versus 22.3 pg/mL (postinjection), p < 0.0001), PlGF (39.5 versus 24.5 pg/mL, p < 0.0001), and PDGF‐A (54.1 versus 47.0 pg/mL, p = 0.0016), while no impact on bFGF levels. For inflammatory mediators, the concentration of TNF‐ α (0.79 versus 0.45 pg/mL, p = 0.0004) and IL‐8 (180.6 versus 86 pg/mL, p < 0.0001) were decreased, while IL‐6 (184.1 versus 333.7 pg/mL, p = 0.0003) and IL‐10 (1.1 versus 1.5 pg/mL, p = 0.0032) were increased. No significant changes in IFN‐ γ or MCP‐1 were detected. Three months after surgery, the mean best‐corrected visual acuity improved from a baseline of 1.8 ± 0.1 logMAR to 0.7 ± 0.1 logMAR ( p < 0.0001), with 36 eyes (90%) achieving an improvement of visual function.
Conclusions
Intravitreal conbercept injection presents dual effects of antiangiogenesis and anti‐inflammation and can be served as an adjuvant treatment to vitrectomy for PDR patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Joint Shantou International Eye Center of Shantou University and The Chinese University of Hong Kong, Shantou, Guangdong, China.
- Department of Ophthalmology & Visual Sciences The Chinese University of Hong Kong, Sha Tin, New Territories, Hong Kong.
- Fifth Clinical Institute Shantou University Medical College, Shantou, Guangdong, China.
ORCID-Profile: Zijing Huang, Weiqi Chen
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Huang, Z., Chen, L. J., Huang, D., Yi, J., Chen, Z., Lin, P., Wang, Y., Zheng, J., & Chen, W. (2024). Preoperative Intravitreal Conbercept Injection Reduced Both Angiogenic and Inflammatory Cytokines in Patients With Proliferative Diabetic Retinopathy. Journal of Diabetes Research. https://doi.org/10.1155/2024/2550367
Vancouver
Huang Z, Chen LJ, Huang D, Yi J, Chen Z, Lin P, et al. Preoperative Intravitreal Conbercept Injection Reduced Both Angiogenic and Inflammatory Cytokines in Patients With Proliferative Diabetic Retinopathy. Journal of Diabetes Research. 2024. doi:10.1155/2024/2550367
BibTeX
@article{Huang2024,
author = {Huang, Zijing and Chen, Li Jia and Huang, Dingguo and Yi, Jingsheng and Chen, Zhiying and Lin, Peimin and Wang, Yifan and Zheng, Jianlong and Chen, Weiqi},
title = {Preoperative Intravitreal Conbercept Injection Reduced Both Angiogenic and Inflammatory Cytokines in Patients With Proliferative Diabetic Retinopathy},
journal = {Journal of Diabetes Research},
year = {2024},
doi = {10.1155/2024/2550367}
}
EUVIMED